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Background and Purpose: Hodgkin lymphoma (HL) treatment has evolved to reduce or
avoid radiotherapy (RT) dose and volume and minimize the potential for late effects. Some
older adolescents are treated on adult protocols. The purpose of this study is to examine
the protocol assignment of older adolescents and its impact on radiation dose to relevant
thoracic structures.
Materials and Methods: Cooperative group data were reviewed and 12 adolescents were
randomly selected from a pediatric HL protocol. Treatment plans were generated per one
pediatric and two adult protocols. Dose volume histograms for heart, lung, and breast
allowed comparison of radiation dose to these sites across these three protocols.
Results: A total of 15.2% of adolescents were treated on adult HL protocols and received
significantly higher radiation dosage to heart and lung compared to pediatric HL proto-
cols. Adolescents treated on either pediatric or adult protocols received similar RT dose to
breast.
Conclusion: Older adolescents treated on adult HL protocols received higher RT dose to
thoracic structures except breast. Level of nodal involvement may impact overall RT dose
to breast.The impact of varying field design and RT dose on survival, local, and late effects
needs further study for this vulnerable age group. Adolescents, young adults, Hodgkin
lymphoma, RT, clinical trials
Keywords: adolescents, young adults, Hodgkin lymphoma, radiotherapy, clinical trials
INTRODUCTION
Hodgkin lymphoma (HL) affects patients of all ages, particularly
adolescents and young adults (ages 16–34). Historically, radio-
therapy (RT) to all involved lymph node volumes was the first
available curative treatment for children and adults. Eventually,
two schools of treatment philosophy evolved. One favored subtotal
nodal irradiation, defined as treating the nodes in the neck, axil-
lae, mediastinum (the traditional mantle field), plus an abdominal
field encompassing spleen, the para-aortic, and pelvic nodes. The
other was more tailored and allowed for treatment of only the
mantle field after staging laparotomy and splenectomy (1). Doses
for both regimens were 40–44 Gy. With the advent of chemother-
apy (CTX), the RT doses decreased slightly. As recently as the
1990s, either subtotal nodal or mantle irradiation to 36–40 Gy was
still administered following CTX (2).
The Quality Assurance Review Center (QARC) has been a
National Cancer Institute (NCI) supported resource, providing
RT quality assurance for several of the NCI Cooperative Groups
performing cancer clinical trials (3). With the NCI transformation
of the Cooperative Group program in March 2014, QARC is now
part of the Imaging and Radiation Oncology Core Group and is
known as IROC RI. During the course of the protocols investi-
gated in this report, RT data were evaluated at QARC to ensure
compliance with Cooperative Group protocol specifications (4).
In the course of performing RT reviews, it became clear that older
adolescents were being treated on both pediatric and adult proto-
cols, for unstated reasons, but presumably due to protocol criteria
or institutional priorities. Adolescents are known to have simi-
lar outcomes to pediatric patients, but their management varied
according to the protocol being followed.
As survival improved, concern shifted to minimizing the late
effects, particularly for children, on growth, vital organs, and car-
cinogenesis. Patient management has evolved to include risk and
response driven adaptive therapy using anatomic and metabolic
imaging (5). In order to avoid the late effects of both thera-
pies, low-risk patients receive only CTX and are not irradiated
on either adult or pediatric protocols. Although this strategy is
commonly used, until protocol data matures, it remains investi-
gational. For intermediate risk patients, the pediatric protocols
now utilize a lower dose of radiation, 21 Gy, with CTX (5). This
strategy is embedded in pediatric trials but influences manage-
ment of adults to a lesser degree. A recent pediatric protocol, COG
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AHOD0031, randomized patients achieving rapid early response
and a complete response (CR) to no RT vs. low dose involved field
irradiation. Similar trials of CTX-only strategies in low-risk adult
patients showing early metabolic CR to initial CTX are matur-
ing, with early results showing a higher risk of recurrence if RT is
omitted but without differences in survival (6, 7).
Given the variation in treatment strategy and the known impor-
tance of dose delivered to normal organs on risk of late effects, we
decided to explore further the issue of protocol assignment for late
adolescents and young adults, aged 16–21 years. The first objective
was to ascertain the proportion of patients assigned to either a
pediatric or adult protocol. The next objective was to examine the
impact of protocol specified radiation regimens on dose to lung,
heart, and breast. It was hypothesized that, for patients requir-
ing RT, the treatment plans specified on these pediatric protocols
would deliver significantly less RT to relevant thoracic normal
structures, heart, lung and, for females, breast, than adult proto-
cols. The final objective was to discuss the relationship between
dose, late effects, survival, and factors that should be taken into
consideration before treatment assignment as well as directions
for further research in this important area.
MATERIALS AND METHODS
Cooperative group HL data were reviewed to identify adolescent
patients, aged 16–21 years, based on the youngest patients allowed
on the adult trials (≥16 years) and the oldest on the pediatric tri-
als (≤21 years). The pediatric trials were POG 9425, POG 9426,
CCG59704, COG AHOD0031, AHOD03P1, and AHOD0431. The
adult trials included were SWOG 9133 (an example of subtotal
nodal/mantle treatment, although treatment data was not in the
QARC database), ECOG 2496, SWOG 9901, and CALGB 50203.
The first of these trials opened in 1992 and the last closed in 2010
(Table 1). The choice of protocol varied, apparently dependent on
institutional priorities, treating medical oncology service, or avail-
able open protocols in a particular facility. CTX regimens were
diverse in agents and duration. Each patient on protocol had con-
sented to the use of their data as part of the IRB process approved
at each treating institution.
Because COG AHOD0031 (pediatric trial) required submis-
sion of pretreatment diagnostic images and treatment portals for
pre-review, and closed shortly after the advent of digital imaging,
a limited number of digital image sets were available for review.
Twelve patients with complete digital image sets were randomly
selected for analysis. COG AHOD0031 was the largest of the pedi-
atric trials and required involved field radiation therapy (IFRT)
for all patients except for those who achieve a rapid early response
by volumetric criteria (CT or MRI) after two cycles of CTX AND
a CR after four cycles of CTX. These patients were randomized to
receive or not receive IFRT.
Their plans had been reviewed at QARC for compliance with
protocol guidelines. Ten patients, seven females and three males,
had stage I or II (supra-diaphragmatic) disease and one male and
one female had stage III disease. Treatment plans for these adoles-
cents were reviewed to examine the impact of treatment variation
on dose to three normal structures: lung,heart, and breast. Figure 1
shows the field definitions for AHOD0031. It was decided the radi-
ation doses, these 12 patients actually received on the pediatric
trial would be compared to the doses they would have received
had they been assigned to two adult trials, ECOG 2496 (Figure 2)
and SWOG 9133 (Figure 3). SWOG 9133 used subtotal nodal
radiation 36–40 Gy, but only the traditional mantle portion that
delivered dose to the thoracic organs was evaluated. The ECOG
adult protocol provided IFRT, 36 Gy/20 fractions, for patients with
bulk disease at presentation, defined as >5 cm for the Stanford V
arm (Arm B), or to the mediastinum for tumor measuring >1/3
chest diameter for the ABVD arm (Arm A). All 12 of the selected
Table 1 | Protocol dates and patient numbers.
Trial Open dates Total
patients
Patients RI Patients
NoRT
Patients
(16–21 years)
Patients
(16–21 years)
RT
Patients
(16–21 years)
NoRT
PEDIATRIC
POG 9426 10/1996–10/2005 293 262 31 81 77 4
POG 9425 03/1997–03/2001 173 158 15 55 52 3
CCG 59704 10/1999–05/2001 9S 56 42 30 21 9
COG AHOD0031 09/2002–10/2009 1715 1176 539 660 462 198
COGAHOD03P1 01/2006–11.2010 1S7 11 176 44 3 41
COGAHOD0431 02/2006–04/2009 277 120 157 105 56 49
Total PEDI 2743 1783 960 975 671 304
ADULT
SWOG 9133 09/1992–04/2000 348 348 0 45 45 0
ECOG 2496 04/1999–06/2006 855 512 343 118 81 37
Arm A 429 180 249 59 27 32
Arm B 426 332 94 59 54 5
SWOG 9901 04/2000–11/2001 11 0 11 1 0 1
CALGB 50203 05/2004–09/2006 98 0 98 11 0 11
Total ADULT 1312 860 452 175 126 49
Total combined 4055 2643 1412 1150 797 353
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FIGURE 1 |Treatment field definitions for AHOD0031.
FIGURE 2 |Treatment field definitions for ECOG 2496 Arm B, planned
on COG protocol image set.
patients met the criteria of 5 cm, disease in the mediastinum, and
would have required RT on ECOG Arm B, but only 4 (including 3
females) had mediastinal disease >1/3 chest diameter and would
have required RT on ECOG Arm A. Therefore, it was decided
to exclude Arm A from the analysis due to insufficient statistical
power (Table 2).
TREATMENT PLANNING MODELING
De-identified pretreatment diagnostic imaging and treatment
planning CT scans were imported into the Varian Eclipse treat-
ment planning system. The original COG AHOD0031 treatment
plans were reconstructed in Eclipse and plans for the adult pro-
tocols were developed on the same CT scan sets in accordance
with the respective protocol guidelines. All these protocols spec-
ified opposed treatment beams to treat the designated target
volumes; 3-dimensional conformal treatment, intensity modu-
lated RT (IMRT), and volumetric modulated arc therapy (VMAT)
techniques were not permitted.
The tumor volumes, protocol specified clinical target volumes,
normal lung and heart, and, for the females, breast volumes were
contoured. For each patient, a plan was generated for each proto-
col, COG AHOD0031, SWOG 9133, and ECOG 2496 Arm B. Each
of these plans underwent standard QARC review to confirm pro-
tocol compliance. For the two IFRT protocol arms, it was elected to
plan the same fields for the pediatric 21 Gy and the adult 36 Gy, to
assess the impact of prescribed dose on the dose to normal organs
of interest (breast, lung, and heart) within each arm. As total nodal
or standard mantle therapy is no longer a component of proto-
col therapy, these fields were not recalculated for the lower dose.
Dose volume histograms (DVHs) were generated and the mean
breast, heart, and lung doses, the V20 for lung and V5 for breast,
heart and lung were recorded for each plan. Treatment fields for
a typical patient with axillary involvement for the AHOD0031
and ECOG Arm B protocols are shown in Figures 1 and 2; this
patient required axillary treatment on both IFRT arms. SWOG
9133 treatment fields are shown in Figure 3.
STATISTICAL METHODS
The difference in dose to the normal structures was evaluated
using analysis of variance by fitting general linear mixed models
(8) (a form of ANOVA for repeated measures). Models were fit by
restricted maximum likelihood estimation (9) using the SAS Proc
Mixed procedure (10). In the presence of significant differences
among means, pairwise comparisons were made using Tukey’s
HSD multiple comparisons procedure (11) utilizing the estimated
covariance matrix to account for correlated observations for analy-
sis of paired comparisons. The distributional characteristics of
outcome measures were evaluated by applying the Kolmogorov–
Smirnov Goodness of Fit Test for Normality (12) to residuals from
fitted linear models and by inspection of frequency histograms of
these residuals. In some cases,natural logarithms of outcomes were
applied to better approximate normally distributed residuals. All
computations were performed using the SAS version 9.2 (13) and
SPSS Version 19 (14) statistical software packages. Statistical sig-
nificance is defined as present when associated p-values are<0.05.
Differences with p-values between 0.05 and 0.10 were described as
“approaching significance.”
RESULTS
Between 1992 and 2010, 1150 patients between the ages of 16 and
21 were treated on North American cooperative group HL proto-
cols, 975 (84.8%) on pediatric protocols, and 175 (15.2%) on adult
protocols. These patients constituted 35.5% of patients enrolled
on these pediatric protocols and 28.3% of patients on these adult
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FIGURE 3 |Treatment field for the SWOG 9133 protocol for patient #4: (A) initial volume to 14 Gy; (B) first volume reduction to 30 Gy; (C) final volume
reduction to 36 Gy.
Table 2 | Selected protocol eligibility criteria and details of protocol specified RT.
Trial Age eligibility Stage eligibility Radiation (RT) dosages and volumes
PEDIATRIC
POG 9426 0–21 years Stage: I, IIA (including IIIA1), disease limited to
spleen, splenic, celiac, or portal nodes
Involved field RT: 25.5 Gy
POG 9425 0–21 years IIB, IIB LMA, IIIB, IV RT dosage: 21 Gy
Stage l and II: mantle RT
Stage III and IV: subtotal or total nodal RT
CCG 59704 < 21 years Stage: IIB. IIIB RT dosage: 21 Gy
IV B RER males: involved field radiotherapy, RER
females, no RT
Slow early response (SER): involved field RT
COG AHOD0031 0–21 years Bulk disease only: IA, IIA CR Pts: randomized, NFT vs. Involved field RT
21 Gy (liver 15 Gy, solid organs 10.5 Gy)
±Bulk disease: IB, IIB, IAE, IIAE, IIIAS,
IIIAE+S:IVA, IVAE
VGPR, PR stable Pts: involved RT, as above
COG AHOD0431 0–21 years Non-bulk disease (−lymphocyte predominant):
IA and IIA
IFRT: 21 Gy
COG AHOD03P1 0–21 years Non-bulk disease (+lymphocyte predominant):
IA and IIA
IFRT: 21 Gy
ADULT
SWOG 9133 ≥ 16 years IA. IEA. IIA, IIEA. no laparotomy, no
infra-diaphragmatic disease
Subtotal nodal radiotherapy
(mantle+ spleen/para-aortic sequential):
36–40 Gy
ECOG 2496 ≥ 16 years Locally extensive: I–IIA/B, III, IV Arm A: 36 Gy, only to initial mediastinal disease,
to residual disease pre-chemo length by
post-chemo width
Arm B: 36 Gy, to bulky disease sites (>5 cm)
+macroscopic splenic disease; to residual
disease pre-chemo length by post-chemo width
SWOG 9901 ≥ 15 years III or IV No radiotherapy
CALGB 50203 ≥ 16 years IA, IB, IIA, IIB, except nodular lymphocyte
predominant
No radiotherapy
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protocols. Of the 1150 patients, 353 (30.7%) were treated with
CTX alone, and 797 (69.3%) with RT, as specified. Of the 975
patients on pediatric protocols, 671 (68.8%) were treated with RT.
Of the 175 patients on adult protocols, 126 (72.0%) were treated
with RT. There was no statistically significant difference in the
percentage of patients treated with RT in the pediatric vs. adult
protocols (X 2= 0.69, p> 0.10).
Table 3 demonstrates the impact of protocol specified fields at
constant dose on normal tissue dose. Table 3A shows that the
SWOG traditional mantle component of the required subtotal
nodal plan delivered significantly more RT dose to heart, lung, and
breast tissue than the ECOG 2496 Arm B adult trial or the pediatric
trial at 36Gy. There were no significant differences between ECOG
2496 Arm B and the pediatric trial at 36 Gy for doses to heart, lung,
or breast. Similarly, Table 3B compares Arm B at 21Gy to pediatric
trial at 21Gy. Again, there were no significant differences in doses
delivered to heart, lung, and breast when each prescription was
reduced to 21Gy. Within each dose (21 or 36 Gy), the ECOG 2496
Arm B and COG AHOD0031 protocols, with differently defined
involved field plans, delivered similar doses to heart, lung, and
breast.
Table 4 compares the V5 for each organ for the mantle, Arm B
and pediatric protocols. As expected, there is statistical difference
between Mantle V5 (36 Gy) and Arm B (36 Gy) and the pediatric
protocol (21 Gy), but surprisingly, no difference between Arm B at
36 Gy and pediatric at 21 Gy for V5 for each of the organs.
Table 5 examines the impact of dose reduction from 36 to
21 Gy within ECOG 2496 Arm B and the pediatric trials. It also
compares RT doses for ECOG 2496 Arm B at 36 Gy to those
for the pediatric trial at 21 Gy, which are the respective proto-
col specified doses. Dose reduction within ECOG 2496 Arm B
from 36 to 21 Gy led to significantly lower doses to heart and
lung but not breast. Similarly, dose reduction from 36 to 21 Gy
within the pediatric trial led to lower doses to heart and lung but
not breast. When ECOG 2496 Arm B 36Gy was compared with
pediatric 21 Gy, the ECOG 2496 Arm B plan delivered signifi-
cantly higher doses to the heart and lung tissue than the pediatric
trial, but there was no significant difference in dosage delivered to
breast.
Figure 4 graphically demonstrates mean and SD for V20 for
lung and V5 and mean dose for each organ.
DISCUSSION
The majority of older adolescents and young adults, aged 16–
21 years, were treated on pediatric protocols. A total of 15.2%
were treated on adult protocols. According to the NCI, 2010 (15)
adolescents and young adults have been more under-represented
in clinical trials than children and middle-aged or older adults.
Reasons include lack of access and referrals to specialized can-
cer centers and until recently, inadequate health insurance. The
proportion of this age group treated off protocol using adult
protocol regimens in community settings may be larger, but is
Table 3 | (A) Impact of treatment arm on normal tissue dose for 36 Gy prescription; (B) impact of treatment arm on normal tissue dose for 21 Gy
prescription.
Mantle Arm B (adult) Pediatric Mantle vs. Arm B Mantle vs. Pediatric Arm B vs. Pediatric
(A)
Heart (mean dose) in Gy 29.8 20.2 19.4 9.6 p<0.0001 10.4 p<0.0001 0.8 p=0.992 (n.s.)
Lung (V20) in percent 51.7 35.1 42.8 16.6 p<0.0001 8.9 p<0.0001 −7.7 p=0.100 (n.s.)
Breast (mean dose) in Gy 12.0 7.0 8.5 5.0 p<0.0009 3.4 p=0.0387 −1.5 p=0.790 (n.s.)
Arm B (adult) Pediatric Arm B vs. Pediatric
(B)
Heart (mean dose) in Gy 11.8 11.5 0.2 p=1.000 (n.s.)
Lung (V20) in percent 21.4 26.0 −4.6 p=0.556 (n.s.)
Breast (mean dose) in Gy 4.1 5.1 −1.1 p=0.939 (n.s.)
Mantle = SWOG (adult); Arm B (adult) = ECOG 2496; Pediatric = COG AHOD 0031; n.s. = not significant.
Table 4 | Heart, lung, and breast V5 analysis by protocol specified treatment prescription.
Arm B
(36 Gy)
Pediatric
(36 Gy)
Pediatric
(21Gy)
SWOG
(36 Gy)
Pediatric
(36 vs. 21 Gy)
Arm B (36 Gy)
vs. Ped. (21 Gy)
SWOG vs. Arm B
(36 Gy)
SWOG vs.
Ped. (21 Gy)
Heart (V5) 67.1 64.8 60.1 100 4.7 7 37.8 39.9
(95% Conf. Int.) (53.0–81.2) (50.6–78.9) (46.0–74.2) (85.9–114.1) p=0.9363 (ns) p=0.7719 (ns) p<0.0001 p<0.0001
Lung (V5) 47.4 22.3 54.5 76.1 3.9 7.1 28.7 21.6
(95% Conf. Int) (36.2–58.6) (47.2–69.6) (43.2–65.7) (64.9–87.3) p=0.7614 (ns) p=0.2875 (ns) p<0.0001 p<0.0001
Breast (V5) 25.1 33.4 30.5 49.6 2.9 −5.4 24.5 19.1
(95% Conf. Int.) (12.6–37.7) (20.8–45.9) (17.9–43.1) (37.1–62.2) p=0.9676 (ns) p=0.7561 (ns) p<0.0001 p=0.0019
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Table 5 | Impact of dose reduction on normal tissue dose by treatment arm.
Arm B
(36 Gy)
Arm B
(21 Gy)
Pediatric
(36 Gy)
Pediatric
(21Gy)
Arm B (36
vs. 21 Gy)
Pediatric
(36 vs. 21 Gy)
Arm B (36 Gy)
vs. Ped. (21 Gy)
Heart (mean dose) 20.2 11.78 19.39 11.54 8.42 7.85 8.66
(95% Conf. Int.) (15.47–24.92) (7.05–16.51) (14.66–24.11) (6.82–16.27) p=0.0003 p=0.0009 p=0.0002
Lung (V20%) 35.09 21.42 42.75 26 13.67 16.75 9.09
(95% Conf. Int.) (25.39–44.76) (11.72–31.11) (33.06–52.44) (16.31–35.69) p=0.0004 p<0.0001 p<0.0001
Breast (mean dose) 7.01 4.09 8.52 5.21 2.92 5.6 1.8
(95% Conf. Int.) (4.11–9.90) (1.19–6.98) (5.62–11.41) (2.31–8.10) p=0.1257 (ns) p=0.045 p=0.6356 (ns)
FIGURE 4 | Graphic presentation of lung, breast and heart mean dose and V5, and Lung V20. Error bars represent±SD.
not known. Community treatment is more likely to be adminis-
tered by oncologists with greater experience with adult treatment
regimens.
Treatment regimens that treat only involved fields, as defined on
either adult (ECOG 2496 Arm B) or pediatric (COG AHOD0031)
protocols, treat smaller volumes of normal tissue than traditional
mantle fields (SWOG 9133). Furthermore, the protocol defined
involved fields of the adult and pediatric protocols, although they
seem quite different, would deliver the same dose to the normal
structures, if the protocol specified doses were identical, either at
36 or 21 Gy. However, consistent with our original hypothesis, at
the protocol prescribed dose of 36 Gy for adult trials and 21 Gy for
pediatric trials, the adult trial delivered significantly higher doses
to the heart and lung than the pediatric trial.
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Of note, the hypothesis that breast tissue would receive signif-
icantly less RT dose on pediatric compared with adult trials was
not fully supported (Table 5). The adult trial allowed axillary treat-
ment only for nodes >5 cm while the pediatric protocol required
axillary treatment for any nodal involvement. Only eight female
patients were included in this study and only some received axil-
lary treatment. Further investigation in larger samples is needed
to evaluate if patients on pediatric protocols, with different field
designs, receive a greater mean breast dose at 21 Gy than they
would on adult regimens at 36 Gy.
In addition to small sample size, this study was also limited by
the inclusion only of patients treated on these particular proto-
cols. There is no way to know how many patients in this age group
were treated off any protocol in this time period, or whether they
were treated by adult or pediatric hematologists. And there is very
limited outcome or late effects data on adolescents, because they
are treated and followed on protocols combined with either adults
or children.
Current National Cancer Cooperative Network (NCCN)
Guidelines, 2014 (16) (which specifically exclude adolescents) rec-
ommend use of the lowest possible RT dose (range 20–36 Gy) and
smallest volume for all HL patients based on bulk disease, stage,
and CTX regimens. Furthermore, the guidelines recommend that
axilla treatment is to be avoided in females if these regions are
uninvolved.
However, questions remain on the optimal management of
adolescents for long-term HL survival. Meyer et al. (17) recently
found in a study of adults that patients have better long-term
survival if treated without RT. However, their study randomized
only patients with non-bulky stage IA and IIA disease to subtotal
nodal radiation (35 Gy) or not. All these patients would have been
excluded from RT on either the ECOG or pediatric trials. For local
control, Wolden et al. (18) demonstrated significantly decreased
10-year event free survival in pediatric patients enrolled on study
CCG 5942 who were “spared” RT, although there was no differ-
ence in overall survival at 10 years. IFRT requires treatment of the
entire nodal region but the definition of involved field has been
shrinking.
One limitation of this study is that it compared dosimetry of
recently completed protocols, which had accrued patients between
1992 and 2010, and whose design dates back to the 1980s. During
the past quarter century, our approach for both adults and children
to the combination of radiation and CTX in HL has undergone
dramatic changes in treatment target, dose, and technique with
the aim of reducing the risk of damage to critical normal tissues.
The first strategy is a reduction of the radiation target vol-
ume from one targeting both known nodal involvement sites and
elective volumes to one targeting only initially involved nodes.
This technique of involved node radiation therapy was originally
described by investigators from Vancouver and Germany (19, 20)
and more recently has been codified in publications from the inter-
national lymphoma radiation oncology group (ILROG) (21). The
ILROG has suggested both involved node RT when patients can
have planning CT/PET scans done in treatment position prior to
the start of CTX and a slightly broader approach termed “involved
site RT” then this information is not available. Both approaches
target only those nodes known (by virtue of enlargement or FDG
uptake) on pre-CTX imaging, do not treat nodal “fields” or other
elective volumes.
A second approach reduces the dose to the targeted volume,
typically from the doses initially used when using radiation as a
single modality of 36–44 Gy to doses in the range of 20–30 Gy.
Such straightforward reductions in irradiated volume and high-
dose volume would be expected to reduce the risk of both second
malignancies and late cardiovascular damage. At least for adults,
the best data for reductions to 20 Gy are for a carefully selected
group of very favorable patients (stage I–IIA, no more than two
sites of disease, no masses >5 cm) and extrapolation of the reg-
imen of two cycles of ABVD and 20 Gy to patients with more
advanced disease are not well supported (22).
A third technique has been to switch from the older AP/PA
beam arrangements, which were typical of HL treatment through
the 1990s to more conformal beam arrangements, typically using
IMRT or VMAT. A number of groups have published data on the
reductions in dose to critical normal tissue (e.g., breast and heart)
while achieving high conformality around the target volume,
which can be achieved with these techniques, both for patients
with typical extent of disease and those with bulky mediastinal
adenopathy (23, 24). This gain in conformality of the high-dose
volume is, however, typically achieved by treating much larger vol-
umes of surrounding tissue to lower doses. While clearly beneficial
in reducing acute toxicity the implications of this for late effects
particularly carcinogenesis in breast and lung (25) are uncertain
and estimates of risk have been highly dependent on the model
used (e.g., linear vs. non-linear) for predicting cancer risk in clin-
ically relevant dose ranges (26, 27). The decision between AP/PA,
conformal, and IMRT/VMAT treatments should be made on a
case-by-case basis after careful review of plans generated with each
of these techniques and may entail a discussion with the patient of
tradeoffs between early vs. late treatment toxicities (28).
The next steps under investigation in children and adults
include use of metabolic response driven treatment adaptation,
potentially allowing further decrease in radiation treatment vol-
ume (4,5) and use of protons, further decreasing treatment volume
(29). There is concern about and neutron contamination from
protons possibly increasing late carcinogenesis while reducing
acute toxicity (30, 31). If possible, future studies should report
on adolescents separately.
Late effects, such as secondary malignant neoplasms (SMNs)
(31) and cardiovascular disease (32), may seriously impact long-
term survival (33), using a pediatric model, Maraldo et al. deter-
mined that decreased field size and RT prescription dose were
associated with a lower estimated risk of late effects and better
survival. Similarly, Yeh and Diller (34) examined the trade-offs
between short- and long-term mortality risks associated with RT
in a hypothetical cohort of pediatric (15 years old) HL patients.
Disease-specific lifetime mortality risk was lower with chemora-
diotherapy (2%) compared with CTX alone (3.6%). However, the
risk of excess late-effects mortality was lower with CTX alone
(1.8%) compared with chemoradiotherapy (7.4%). Overall con-
ditional life expectancy was 57.2 years with CTX alone compared
with 56.4 years with chemoradiotherapy, suggesting that initial
single modality treatment may provide better overall survival. For
children and adolescents, many decades of follow-up are required,
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especially if event free survival is being regarded as questionable
surrogate for long-term overall survival in HL.
To better understand the impact of late effects, Travis et al. (35)
recently recommended research priorities in assessing interactions
between RT and numerous confounding factors such as age, sex,
race, substance use, diet, and genetic susceptibility with a focus on
adolescents and young adults. For example, should treatment be
altered for the young woman who has a strong family history of
breast cancer with or without known BRCA mutation or the young
man whose father died of a myocardial infarction while jogging at
age 45?
In conclusion, adolescents treated on this adult protocol would
have received higher RT dose to heart and lung compared to those
on this pediatric protocol. The effect on breast dose was less clear
and requires further study, with greater statistical power. Nev-
ertheless, any radiation exposure requires careful records of the
details of treatment, especially RT dose and field design, and very
long-term follow-up for local control, late effects, and overall sur-
vival. This paper suggests that careful records of DVHs for normal
organs should be kept for late effect analysis for every patient, on
or off protocol. Until more research is available, adolescents and
young adults should be treated on cooperative group protocols to
the extent possible, and if not, an off protocol treatment regimen
for each HL patient should be designed on a case-by-case basis
with attention to field design, RT dose, and factors that may exac-
erbate late effects based on detailed medical history, to maximize
long-term survival and quality of life.
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